Scholarlink

Purpose <p>Anamorelin hydrochloride (ANAM), used to treat cancer cachexia, is often discontinued early in clinical practice. Herein, we explored the clinical factors associated with the early discontinuation (Ed) of ANAM and examined its effect on treatment outcomes.</p> Methods <p>Clinical data of patients with gastrointestinal cancers who were administered ANAM between April and November 2021 from 16 institutions were retrospectively collected. Ed was defined as ANAM discontinuation within 4 weeks of initiation. ANAM efficacy was compared between the continuation (Co) and Ed groups.</p> Results <p>Of the 123 patients, 50 had an Ed of ANAM. The most common reasons were cancer progression (36%), adverse events (30%), and insufficient efficacy (22%). Age ≥ 75 years (odds ratio [OR] 4.11, 95% confidence interval [CI] 1.418–11.952, <i>p</i> = 0.009), no concomitant anticancer chemotherapy (OR 8.84, 95% CI 1.900–41.151, <i>p</i> = 0.006), and modified Glasgow prognostic score 2 (OR 2.65, 95% CI 1.065–6.604, <i>p</i> = 0.036) were significant risk factors for Ed. At 3 ± 1 weeks after ANAM initiation, the number of patients with increased appetite (Co 50.8% vs Ed 14.3%, <i>p</i> = 0.012) and food intake (Co 59.2% vs Ed 20.0%, <i>p</i> = 0.002) were significantly higher in the Co group than in the Ed group.</p> Conclusion <p>Initiating ANAM while patients can still receive concurrent chemotherapy may help prevent Ed and achieve better therapeutic benefit.</p> <p>Trial registration</p> <p>The registration number in the UMIN Clinical Trial Registry is UMIN000051550. The date of registration is July 7, 2023.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Kazuaki Harada,
  • Shinya Kajiura,
  • Kentaro Sawada,
  • Kazuteru Hatanaka,
  • Atsushi Sato,
  • Ken Ito,
  • Hotaka Tamura,
  • Ayako Doi,
  • Takayuki Ando,
  • Michio Nakamura,
  • Hiroshi Nakatsumi,
  • Tetsuhito Muranaka,
  • Susumu Sogabe,
  • Takahiro Ishii,
  • Shintaro Nakano,
  • Masayoshi Dazai,
  • Yusuke Sasaki,
  • Yasuyuki Kawamoto,
  • Satoshi Yuki,
  • Yuh Sakata,
  • Yoshito Komatsu

摘要

Purpose

Anamorelin hydrochloride (ANAM), used to treat cancer cachexia, is often discontinued early in clinical practice. Herein, we explored the clinical factors associated with the early discontinuation (Ed) of ANAM and examined its effect on treatment outcomes.

Methods

Clinical data of patients with gastrointestinal cancers who were administered ANAM between April and November 2021 from 16 institutions were retrospectively collected. Ed was defined as ANAM discontinuation within 4 weeks of initiation. ANAM efficacy was compared between the continuation (Co) and Ed groups.

Results

Of the 123 patients, 50 had an Ed of ANAM. The most common reasons were cancer progression (36%), adverse events (30%), and insufficient efficacy (22%). Age ≥ 75 years (odds ratio [OR] 4.11, 95% confidence interval [CI] 1.418–11.952, p = 0.009), no concomitant anticancer chemotherapy (OR 8.84, 95% CI 1.900–41.151, p = 0.006), and modified Glasgow prognostic score 2 (OR 2.65, 95% CI 1.065–6.604, p = 0.036) were significant risk factors for Ed. At 3 ± 1 weeks after ANAM initiation, the number of patients with increased appetite (Co 50.8% vs Ed 14.3%, p = 0.012) and food intake (Co 59.2% vs Ed 20.0%, p = 0.002) were significantly higher in the Co group than in the Ed group.

Conclusion

Initiating ANAM while patients can still receive concurrent chemotherapy may help prevent Ed and achieve better therapeutic benefit.

Trial registration

The registration number in the UMIN Clinical Trial Registry is UMIN000051550. The date of registration is July 7, 2023.